Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) was $2.68 for the day, up 4.28% from the previous closing price of $2.57. In other words, the price has increased by $4.28 from its previous closing price. On the day, 16.63 million shares were traded. IOVA stock price reached its highest trading level at $2.71 during the session, while it also had its lowest trading level at $2.45.
Ratios:
Our analysis of IOVA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.64 and its Current Ratio is at 4.18. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 16, 2025, UBS Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $2.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 05 ’25 when Kirby Daniel Gordon bought 30,000 shares for $1.84 per share. The transaction valued at 55,200 led to the insider holds 30,000 shares of the business.
Puri Raj K. bought 5,600 shares of IOVA for $9,743 on May 23 ’25. The Chief Regulatory Officer now owns 206,852 shares after completing the transaction at $1.74 per share. On May 14 ’25, another insider, Vogt Frederick G, who serves as the Interim CEO & General Counsel of the company, bought 25,000 shares for $1.69 each. As a result, the insider paid 42,250 and bolstered with 374,646 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 894943168 and an Enterprise Value of 588952128. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.21 while its Price-to-Book (P/B) ratio in mrq is 1.17. Its current Enterprise Value per Revenue stands at 2.769 whereas that against EBITDA is -1.613.
Stock Price History:
The Beta on a monthly basis for IOVA is 0.88, which has changed by -0.638814 over the last 52 weeks, in comparison to a change of 0.20277917 over the same period for the S&P500. Over the past 52 weeks, IOVA has reached a high of $12.51, while it has fallen to a 52-week low of $1.64. The 50-Day Moving Average of the stock is 25.45%, while the 200-Day Moving Average is calculated to be -47.66%.
Shares Statistics:
IOVA traded an average of 18.51M shares per day over the past three months and 33773710 shares per day over the past ten days. A total of 333.93M shares are outstanding, with a floating share count of 271.49M. Insiders hold about 18.70% of the company’s shares, while institutions hold 63.72% stake in the company. Shares short for IOVA as of 1752537600 were 98633209 with a Short Ratio of 5.33, compared to 1749772800 on 90964131. Therefore, it implies a Short% of Shares Outstanding of 98633209 and a Short% of Float of 32.349998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The company has 9.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.18 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.87 and -$1.18 for the fiscal current year, implying an average EPS of -$1.08. EPS for the following year is -$0.69, with 9.0 analysts recommending between -$0.12 and -$1.04.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 11 analysts. It ranges from a high estimate of $75.9M to a low estimate of $55.16M. As of the current estimate, Iovance Biotherapeutics Inc’s year-ago sales were $31.11MFor the next quarter, 11 analysts are estimating revenue of $78.32M. There is a high estimate of $84.01M for the next quarter, whereas the lowest estimate is $73.8M.
A total of 11 analysts have provided revenue estimates for IOVA’s current fiscal year. The highest revenue estimate was $300.4M, while the lowest revenue estimate was $261.6M, resulting in an average revenue estimate of $287.11M. In the same quarter a year ago, actual revenue was $164.07MBased on 11 analysts’ estimates, the company’s revenue will be $481.4M in the next fiscal year. The high estimate is $634.1M and the low estimate is $375M.
